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Summary
The recognition of virus-infected cells by class I MHC-restricted cytotoxic T cells requires
endogenous processing ofantigen for presentation. It is still unclear whether endogenous processing
of antigen can be utilized by class 11 MHC molecules for presentation. To test this possibility,
a human B cell line expressing HLAA2 and HLA-DR1 was infected with a recombinant vaccinia
virus expressing the Influenza A virus M1 matrix protein (VAC-M1) and was assayed for lysis
by different M1-specific cytolytic T cell lines, restricted by either HLA-A2 or by HLA-DR1.
Class II-restricted lysis ofVAC-M1-infected cells did occur. This lysis required de novo M1 synthesis
and was not due to exogenous antigen. Several properties of the endogenous processing pathway
for class 11-restricted presentation were different from those of the pathway utilized by class
I molecules. First, class II-mediated recognition of VAC-M1 infected cells was less efficient, requiring
higher doses of virus and longer infection times, than the class 1-mediated recognition. Second,
chloroquine completelyblocked presentation of endogenous M1 to class 11-restricted T cells but
had no effect on the class I-restricted presentation. Third, the class II-restricted presentation
of M1 was only mildly affected by Brefeldin A, a drug that prevents transport from the endoplasmic
reticulum to the Golgi, whereas the class I-restricted presentation ofM1 was completely abrogated
by this drug. These data demonstrate the existence of an endogenous processing pathway for
the presentation of cytosolic antigen by class 11 molecules and show that this pathway is distinct
from the one used for presentation by class I molecules.
Antigen processing refers to the multiple biochemical and
1 .1 cellular events that lead to the formation of an immuno-
genic complex between a foreign antigen and an MHC mol-
ecule of the presenting cell, such that this complex can be
recognizedby a T cell. The processing requirements for pre-
sentation by class I or by class 11 MHC molecules differ. Ex-
ogenous antigen, in the form of inactivated virus or soluble
protein, can be efficiently processed by antigen presenting
cells, such as B cells and macrophages, for presentation by
class 11 molecules (1). In contrast, class I molecules generally
do not present exogenous protein antigen (2, 3), at least not
in vitro (4). The exogenous processing pathway involves an-
tigen uptake by the presenting cell and delivery of antigen
into an acidic intracellular compartment where processed frag-
ments may bind to newly synthesized class 11 molecules on
their way to the cell surface (5, 6). Class II molecules inter-
nalized from the cell surface may also contribute to the pre-
sentation of exogenous antigen by murine B cells (7, 8). The
exogenous processing pathway can be blocked by agents, such
as chloroquine, that prevent acidification of intracellular or-
ganelles.
The main requirement for presentation by class I mole-
cules seems to be the presence of antigen in the cytosol (2,
9). Peptide fragments, presumably derived from cytoplasmic
degradation of the antigen, may translocate into the en-
doplasmic reticulum where they bind to newly synthesized
class I molecules (10, 11) . Peptide fragments synthesized
directly in the cytosol from mini-gene constructs inserted into
recombinant vaccinia viruses were efficiently presented by class
I molecules (12-14) but not by class II molecules (14). The
inability of class II molecules to present endogenously syn-
thesized transmembrane hemagglutinin of influenza virus (3)
led to the proposal that class 11-restricted presentation was
limited exclusively to exogenous antigens (15, 16).
However, an obvious pathway for the processing ofendog-
enous cell surface antigens for class 11-mediated presentation
would be internalization into an endosomal compartment.
Several studies on the presentation of membrane-associated
antigens are compatible with this possibility (17-22). Although
internalization of endogenously synthesized surface antigen
for class II-mediated presentation would represent a pathway
similar to uptake ofexogenous antigen, it is notably different
in that it would enable the immune system to encounter cell-
specific self antigen in the context of class II molecules. Be-
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cules could potentially affect many immune functions, such
as selection of T cells in the thymus, peripheral T cell toler-
ance, autoimmunity, alloreactivity, and thegeneration of help
after viral infections, it is important to determine whether
cellular mechanisms exist that lead to class II-restricted pre-
sentation of endogenous cytoplasmic antigens.
Whether cytosolic antigen can be processed endogenously
for class II-restricted presentation is still debated. Hepatitis
B surface antigen synthesized endogenously from a recom-
binant vaccinia viruswas processed for classII-restricted pre-
sentation, as measured in a4-dproliferation assay (23). This long
infection time and the unusual membrane association of this
antigen make it difficult to distinguish between internaliza-
tion and cytosolicprocessing as potential mechanisms for pre-
sentation. It remains important to test whether such endog-
enous processing forclassII-restrictedpresentation is applicable
to cytosolic antigens. Murine L cell fibroblasts transfected
with measlesvirusgenesencoding cytosolic proteins did pro-
cess these antigens endogenously for presentation to CD4+
cytotoxic T cells (24). However, thelack of human invariant
chain in those transfected cells may account for their ability
to utilize an endogenous processing pathway (25). Another
study, using cells incubated with influenza virus at an acid
pH, and treated simultaneously with chloroquine andBrefeldin
A, concluded that class II molecules can utilize the endoge-
nous cytoplasmic pathwayused by class I molecules (26). This
conclusion is difficult to reconcile with the evidence that a
pre-processed cytoplasmic peptidecontaining epitopes forboth
class I- andclass II-restrictedTcells, expressedfrom a recom-
binant vaccinia virus, was presented by class Ibut not by class
II molecules (14), unless the ad hoc assumption is made that
vaccinia virus infection selectively inhibits the transport of
class II molecules.
In this study, a recombinant vaccinia virus encoding the
M1 matrix protein of influenza A virus (VAC-Ml)l was used
to test whether cytosolic processing wouldlead to presenta-
tion of a HLADR1-restricted M1 epitope, in addition to a
HLAA2-restricted epitope. Direct evidence is provided that
endogenously processed M1 protein canbe presented to class
II-restricted cytolytic T cells. Furthermore, kinetic and phar-
macological properties of theM1 processing forclass II-medi-
ated presentation suggest that distinct endogenous pathways
are used specifically forpresentation by either oneor the other
class of MHC molecules.
Materials and Methods
Cells.
￿
Thehemizygous HLA-A2,DR1 EBVtransformed cellline
45.1 (27) wasused as target cell in allexperiments. Cells were main-
tained in RPMI 1640 (Hazelton Biologics Inc., Lenexa, KS) sup-
plementedwith 2 mM glutamine, 10 hg/ml gentamicin and 10%
heat-inactivated FCS.
TCeII Lines.
￿
Tcell lines 109.2B2 and 130AC6 areHLA-DR1-
restricted and recognize influenza A Ml matrix derived peptide
1 Abbreviation used in this paper: VAC-Ml, recombinant vaccinia virus
encoding the influenza A virus M1 matrix protein.
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17-31 (26). HLA-A2-restricted T cell line 161 recognizes the Ml
peptide 56-68 (28). All lines were generated in limiting dilution
at 10 cells/well by direct stimulation with peptide andwere kindly
provided by W. Biddison (Neuroimmunology Branch, National
Institute of Neurological Disorders and Stroke, NIH). T cell lines
were grown in Iscove's modified Eagle's medium supplemented with
10% heat-inactivated human A* serum, 10 jug/ml gentamicin,
and 10 U/ml recombinant 11,2 (kindlyprovided by theCetusCorp.,
Emeryville, CA). The cells were maintained by weekly stimula-
tion with irradiated (8,000 rad) feeder cells consisting of a 10:1
mixture of mononuclear cellsand45.1 cellstreated with 10 Wg/ml
of the corresponding peptide for 2-3 h at 37°C, washed, and
resuspended in the same medium.
Antigens.
￿
Purified InfluenzaAM1 matrix was a gift ofJ. Yew-
dell (Laboratory of Viral Diseases, National Institute of Allergy
and Infectious Diseases, NIH). MI peptides 17-31 and 56-68were
kindly provided byJ. Rothbard (Imperial Cancer Research Fund,
London, UK) and W Biddison, respectively.
Virus.
￿
InfluenzaA/Sichuan/2/87 virus was obtained from M.
Williams (Centerfor Biologic Evaluation and Research, Food and
Drug Administration, Bethesda, MD) as infectious allantoicfluid.
Purified (1.6 x 101° PFU/ml) recombinant vaccinia virus con-
taining the influenza Ml gene (VAC-Ml) has been described (29)
and was kindly provided by Dr. B. Moss (Laboratory of Viral Dis-
eases, National Institute of AllergyandInfectious Diseases,NIH) .
UVinactivation of influenza or vaccinia virus was achieved by a
15-min exposure to 1,200 pW/CMZ of a short-wave UV light.
Target Sensitization.
￿
For peptide sensitization, 5 x 105 45 .1
cells were cultured with 10 Ag/ml peptide in RPMI 1640 with
5% FCS for i h, unless otherwise indicated, at 37°C. The same
wasdone for sensitization with M1 protein at different concentra-
tions. For infections with recombinant vaccinia virus, 5 x 105
"Cr-labeled 45.1 cells were resuspended in 500 p1 RPMI 1640
with 5% FCScontaining different doses(25, 50, or 100PFU/cell)
of purified virus. After 1 h on a rotator at 37°C, 1 ml medium
was added and the cells were kept under continuous rotation for
a further 0, 1, or 4 h, for a total of 1, 2, or 5 h of infection. Cells
were then washed, counted, and used as targets for CTL assays.
For experiments requiring chloroquine treatment, "Cr-labeled
target cells were washed and preincubated for 10 min in medium
containing 80 fAM chloroquine (Sigma Chemical Co., St . Louis,
MO)before sensitization. Thesame concentration ofchloroquine
was maintained throughout sensitization (including washes), but
it was reduced to 10 WM for the CTL assay. Anisomycin (Sigma)
and Brefeldin A (kindly provided by R. Klausner, Cell Biology
and Metabolism Branch, National Institute of Child Health and
HumanDevelopment, NIH) were used at 26 Ag/ml and0.5 Ag/ml,
respectively, at the time of sensitization, and were maintained at
the same concentration during the CTL assays.
Cytotoxicity Assays.
￿
Cytolytic activity was measured by stan-
dard 4-h "Cr-release assays. Target cellswere labeled with 100 hiCi
"Cr for 1 h at 37°C and washed in RPMI 1640 with 5% FCS.
After the first wash, targets were sensitized or infected, washed
again, counted, andresuspended in the same medium at a concen-
trationof 40,000 cells/ml. 2,000targets perwell (50 P,l) were mixed
with 100 ul effector cells at different ratios in V-bottomed micro-
titer plates (Nunc, Roskilde, Denmark). Supernatants were har-
vested and counted. Percent specific "Cr-release was calculated as:
100 x [(release by CTL - spontaneous release)/(maximum re-
lease - spontaneous release)].Allpoints were mean cpmfrom dupli-
cate experiments against triplicate controls formaximum andspon-
taneous release. Maximum and spontaneous releases were defined
as cpm released from targets incubated with 100 Al 0AM HCl or100p,l medium, respectively. Spontaneous release ranged between
15-30% of the maximum release in all experiments.
Cell Mixing Experiments.
￿
In a typical experiment with VAC-
Ml, infection of
51Cr-labeled cells starts with a 1-h incubation
with concentrated virus to allow entry, followed by adilution and
further incubation for 4 h to allow infection to proceed, and by
a 4-h CTL assay during which infection of the target cells con-
tinues. Even though processing of exogenous M1 can take place
in only 1 h, arigorous mixing experiment was designed in which
uninfected "Cr-labeled cells were mixed with VAC-M1-infected
cells for 4 h before and during the 4 h CTL assay. To reduce the
possibility of virus spreading to uninfected cells during the co-
culture, cells infected with VAC-Ml for 2 h were washed before
mixing. To control that a wash 2 h after addition of VAC-Ml did
not reduce the efficiency of VAC-Ml infection, and that mixing
per se did not reduce lysis by CTL, a reverse mixing experiment
with "Cr-labeled infected cells and unlabeled uninfected cells was
carriedout. Afterthe2h ofinfectioncellswere washed andcounted.
200,000 cells were mixed with equal numbers of5'Cr-labeled unin-
fected 45 .1 cells and incubatedfor4 h at 37°C in continuous rota-
tion. Cells were then washed andresuspended in RPMI 1640 with
5% FCS to a concentration of 80,000 cells/ml. 50 p.l of this mix-
ture (containing 2,000cellsofeach type) were then used as targets
for CTL assays.
Results
Specificity ofthe Cytolytic T Cell Lines.
￿
T cell lines used
here were specific for the HLA-A2-restricted epitope of the
Influenza A virus M1 antigen, or the HLA-DR1-restricted
M1 epitope. The B cell line 45.1 expressing A2 and DRI
was chosen as target for CTL assays. The T cell line 161 is
specific for the M1 peptide 56-68 in the context of A2, and
T cell lines 109.2132 and 130.1C6 recognize the M1 peptide
17-31 presented by DRl (Fig. 1). In addition, the DRl-
restricted T cell lines 109.2132 and 130.1C6 lysedtargets treated
with the purified M1 protein. Fig. 2a showsresults obtained
with theline 130.1C6. Recognition oftarget cellsby theDR1-
restricted lines required three orders of magnitude less Ml
protein than M1 peptide 17-31, on a molar basis. Addition
of chloroquine to the target cells during sensitization with
M1 protein inhibited the cytolysis; complete inhibition re-
V7
O
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Figure 1.
￿
Lysis of HLA-A2,DR1 B cells pulsed with influenza A
matrix peptides M1 17-31 (/) and 56-68 (O) or untreated cells (0)
by A2-restricted line 161 (a) and by DRl-restricted T cell lines
109.2B2 (b) and 130.1C6 (c).
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Figure 2.
￿
Recognition of Ml protein by DRl-restricted Ml-specific
T cell line 130AC6. (a) Titration of matrix protein recognition by
130.1C6 ("), compared with M1 17-31 peptide (/); (b) chloroquine
inhibition of processing and presentation of the Ml protein. Target
cells in the presence of chloroquine were pulsed with 10.7 nM (0.3
,ug/ml) Ml protein (") or 6 uM (10 ug/ml) Ml 17-31 peptide (/)
for 1 h before the CTL assay.
quired 80 /AM chloroquine (Fig. 2 b). Whereas processing
of inactivated influenza virusforpresentation was also chlo-
roquine-sensitive (data not shown), presentation of the M1
peptide 17-31 was not inhibited (Fig. 2 b).
Target Cells Infected with VAC-M1 Are Lysed by Both Class
I- and Class 17-restricted M1-specfic T Cell Lines. 45.1 cells
were infected for 5 h with increasing doses of VAC-M1 and
tested for lysis by the A2- or the DR1-restricted M1-specific
lines (Fig. 3 a). Class I-mediated lysis was more efficient:
at 25 PFU/cell it exceeded the class I1-mediated lysis obtained
at 100 PFU/cell. 45.1 cells were infected with 100 PFU/cell
for increasing times and tested for lysis (Fig. 3 b). Whereas
M1 presentation by A2 occurred after only 1 h of infection,
presentation by DRI was barely detectable during the first
2 h of infection. This experiment detected true differences
in the kinetics of processing and presentation of Ml, rather
than differences in infection and M1 synthesis, because the
Log concentration (nM)
￿
Ghloroquine (gM)
a
VAC-M1 dose (pfu/cell)
￿
time of infection (hours)
b
Figure 3.
￿
VAC-Ml-infected cells are lysed by HLA-A2- and by
HLA-DRl-restricted CTL. (a) Target cells infected for 5 h with the
indicated dose of VAC-Ml were assayed for lysis by the HLA-A2-
restricted CTL line 161 (O) or by the HLA-DR1-restricted CTL line
109.2B2 (/); (b) target cells infected with 100 PFU/cell of VAC-Ml
for the indicated time were assayed for lysis by the HLA-A2-restricted
CTL line 161 (O) or by the HLA-DRl-restricted CTL lines 109.2B2
(/) and 130.1C6 (").40
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Figure 4.
￿
Recognition of VAC-MI infected cells by DRl-restricted
T cell line 109.2B2 requires de novo Ml protein synthesis. (a) Target
cell were either untreated (p), infected with VAC-Ml (/), or in-
cubated with UVinactivated VAC-Ml (O), for 5 h before the CTL
assay. (b) UVinactivation of influenza A/Sichuan/87 virus did not
affect recognition of target cells by T cell line 109.2B2; target cells
were either untreated (p), infected with influenza virus (A), or in-
cubated with UV-inactivated influenza A virus (A). (c). Effect of pro-
tein synthesis inhibitor anisomycin on the recognition of VAC-Ml in-
fected targets; target cells were either untreated (0) or infected with
VAC-Ml in the absence (M) or presence (O) of 26 hg/ml aniso-
mycin. (d) Effect of anisomycin on the recognition of targets treated
with UV-inactivated influenza virus; target cells were either untreated
(0) or incubated with UV-inactivated influenza virus in the absence
(A) or presence (0) of 26 jug/ml anisomycin.
same infected targets were assayed in parallel with either the
class I- or the class II-restricted cytolytic T cells.
As a specificity control, 45 .1 cells infected with a recom-
binant vaccinia virus encoding the influenza A H3 hemag-
glutinin, and expressing surface H3, were not susceptible to
lysis by either 109 .2112 or 130.1C6 T cell lines (data not
shown).
Lysis of VAC-M1-infected Targets by Class 11-restricted Cell
Lines Requires MI Synthesis. Two control experiments were
carried out to rule out the possibility that the VAC-Ml prep-
aration was contaminated with M1 protein at a level sufficient
to result in exogenous processing for class II-restricted pre-
sentation. Despite the use ofgradient-purified VAC-Ml these
controls were important because, as shown in Fig. 2 a, incu-
bation with as little as 0.03 /ug/ml (1 nM) Ml protein for
1 h leads to presentation. First, when the VAC-MI prepara-
tion was inactivated with UV light, presentation was abol-
ished (Fig. 4 a). UV light does not destroy the M1 epitope
because UVinactivated influenza virus can be presented (Fig.
4 b). Second, treatment of infected cells with the protein syn-
thesis inhibitor anisomycin also abolished Ml presentation
(Fig. 4 c). This demonstrates the requirement for M1 syn-
thesis because anisomycin only inhibited partially the pro-
cessing of exogenous UV-inactivated influenza virus (Fig. 4
d). This inhibition occurred after 5 h of treatment and was
probably due to depletion of class II molecules by protein
synthesis inhibition.
The Processing ofM1 in VAC-M1-infected Cellsfor Class II-
restrictedPresentation Is Endogenous. Rigorous mixing experi-
ments were carried out to test the possibility that Ml pro-
tein accumulated in the medium of VAC-Ml-infected cells,
thus providing an exogenous source of antigen for processing
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Figure 5.
￿
Cells infected with VAC-MI do not sensitize S'Cr-labeled
uninfected targets for recognition by DRl-restricted Ml-specific T
cell lines 109.2B2 (a) and 130.1C6 (b); target cells untreated (0), in-
fected with VAC-MI (/), 1:1 mixture of VAC-MI infected unlabeled
and 5'Cr-labeled uninfected targets (O), and 1:1 mixture of 51Cr-
labeled infected targets with unlabeled uninfected cells (").
and presentation. Uninfected "Cr-labeled 45.1 cells were
mixed with VAC-M1 infected cells for 4 h before and during
the 4-h CTL assay. Fig. 5 shows that (a) the mixing protocol
did not reduce the levelof lysis ofinfected cells, as compared
with the usual protocol without cell mixing, and (b) lysis
of infected cells cannot be accounted for by the presence of
exogenous Ml because uninfected cellswere either not lysed,
or barely so, in the CTL assay. In agreement with the evi-
dence that neither VAC-Ml nor M1 protein was transferred
to uninfected cells, lysis of uninfected cells by class I-restricted
CTL did not occur after mixing with infected cells (not
shown) .
TheEndogenous Processing PathwayforClassII-restrictedMi
Presentation Is Differentfrom the One Usedfor Class I-restricted
Presentation. Class I-restricted antigen presentation appears
to require the acquisition of peptide by a newly synthesized
class I molecule in the endoplasmic reticulum (10, 11). Con-
sistent with this view, processing for class I-restricted pre-
sentation is not inhibited by chloroquine (3) but it is com-
pletely abolished by Brefeldin A (30, 31), a drug that prevents
export of proteins from the endoplasmic reticulum. To test
whether class II molecules might share the endogenous pro-
cessing pathway utilized by class I molecules, inhibition ex-
periments with chloroquine and Brefeldin A were carried out.
Chloroquine was used, under conditions that totally block
presentation of exogenous purified Ml protein, with VAC-
Ml-infected cellsto test its effect on endogenously processed
M1. The same infected cellswere assayed in parallel with ei-
ther the class I-restricted or the class 11-restricted T cell lines
(Fig. 6). The class I-mediated T cell recognition was unaffected
by treatment with chloroquine. This result shows that infec-
tion with vaccinia virus and expression of the M1 proteinEffector to target ratio
Figure 6.
￿
Effect of chloroquine on the recognition of VAC-Ml in-
fected target cells by the class I-restricted T cell line 161 (a) and the
class 11-restricted T cell line 109.2132 (b) . Target cells were either un-
treated (0) or infected for 5 h with VAC-Ml in the absence (/) or
presence of 80 ttM chloroquine (O) .
took place in the presence of chloroquine and, as expected,
that cytoplasmic processing of M1 and its presentation by
class I were not inhibited by this drug. However, the class
1I-mediated response was totally abrogated . This inhibition
can be interpreted in two ways. First, endogenous processing
for class II-mediated presentationmay involve a chloroquine-
sensitive intracellular compartment . Second, the chloroquine
inhibition may not be at the level ofprocessing butmay be medi-
1 :1
￿
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Figure 7.
￿
Effect of Brefeldin A on the recognition of VAC-Ml in-
fected target cells by the class I-restricted T cell line 161 (a) and the
class II-restricted T cell line 109.2B2 (b) . Target cells were either un-
treated (0) or infected for 5 h with VAC-Ml in the absence (N) or
presence of 0 .5 leg/ml Brefeldin A (O) .
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ated by the delayed dissociation of the invariant chain from
the as dimers (32, 33) . If endogenously processed antigen
interacts with class II molecules in the endoplasmic reticulum,
class II-restricted presentation should be inhibited by Brefeldin
A . Target cells were treated with Brefeldin A and infected
withVAC-Ml (Fig. 7) . This 5-h treatment resulted in a com-
plete inhibition of the class 1-mediated presentation . In con-
trast, a mild inhibition of the class II-mediated presentation
was noted. Therefore, transport of class II molecules out of
the endoplasmic reticulum is not required for presentation
of endogenous antigen .
Discussion
The possibility that endogenous processing of cytosolic an-
tigen could lead to presentation by class II molecules was
investigated using a well-defined antigenic system . The Ml
matrix protein of influenzaA virus is a cytosolic antigen with
defined epitopes recognized byT cells restricted by eitherHLA
A2 or HLA-DR1. Human cytolytic T cell lines specific for
the DRl-restricted Ml epitope, as well as aT cell line specific
for the A2-restricted M1 epitope, were used to assay presen-
tation by a HLA-A2,DR1 B-cell line. A recombinant vac-
cinia virus encoding the M1 protein was used to obtain en-
dogenous Ml synthesis in infected cells, in the absence of
an exogenous source ofM1 protein . The influenza virus M1
protein was well suited for this study because it is known
to remain in the cytosol and the nucleus of infected cells (34)
and to remain in the cytosol ofVAC-M1 infected cells, even
after 14 h of infection (29) . As expected, the 45.1 B cell line
used here did not express detectable surface Ml after 5 h of
infection with VAC-M1 (data not shown) .
Unequivocal evidence was obtained that endogenously syn-
thesized Ml protein can be processed and presented by class
II molecules. A purified recombinant vaccinia virus, free of
Ml protein, was used to infect target cells under conditions
that did not lead to detectable accumulation of exogenous
M1 protein. Such infected target cells were lysed by both class
I- and class II-restricted T cells, specific for distinct Ml epi-
topes . The demonstration of an endogenous processing
pathway for presentation of cytoplasmic proteins by class II
molecules was thus derived without relying on assumptions
about the specificity of certain drugs that interfere with cel-
lular functions .
The evidence that a viral cytosolic antigen can be presented
by class II molecules suggests that endogenous self proteins
may also be processed and presented to CD4+ T cells. Con-
trary to a situation where only exogenous antigen can be
presented, this would provide the possibility of cell-specific
antigen presented in the context of class II molecules. Class
II-positive thymic epithelial cells that are responsible for the
positive selection ofCD4+ T cells (35) may indeed, as was
suggested (36), utilize cell-specific peptides to select T cells,
some of which will escape the negative selection mediated
by class II-positive bone marrow-derived dendritic cells in
thymic medulla . Cell-specific presentation ofendogenous pep-
tides could also explain several observations on alloreactive
class II-restricted T cells . Certain alloreactive CD4+ T cellsrecognized the allo-class II molecule only when expressed
on certain cells, e.g., on B cells but not on macrophages (37);
again it was suggested that it was probably due to the recog-
nition of a cell-specific peptide presented by the class lI mol-
ecules. Such a cell-specific peptide need not be derived from
re-uptake of exogenous antigen but may well result from en-
dogenous antigen processing. The rangeof self peptides that
can potentially bind to class II molecules is thus vastly in-
creased. The need to develop tolerance to all endogenously
derived peptides presented at a sufficiently high level places
an additional burden on the immune system. Endogenously
derived peptides also provide potential targets for autoim-
mune reactions. On the other hand, presentation of endoge-
nous antigen has the obvious advantage that T cell help would
be initiated rapidly after infection of class II-positive cells.
Endogenous M1 was less efficientlyprocessed for classII-as-
sociated recognition than for class I-associated recognition,
both in the dose of recombinant vaccinia virus required and
in the kinetics of processing and presentation. These differ-
ences reflect either distinct processing pathways, operating
separately for presentation by the two classes of MHC mole-
cules, or, in the case of a shared pathway, a lower efficiency
in the transport of class II molecules to the cell surface, or
in the processing or the binding of the DR1-restricted epi-
tope. In contrast to the exogenous-endocytic processing for
class II-mediated presentation, cytosolic processing for class
I-mediated presentation is insensitive to chloroquine (3). Treat-
ment with chloroquine, at a dose that totally abolished pro-
cessing of exogenous M1 protein, before and during VAC-
M1 infection, had no effect on the A2-restricted recognition
of infected cells but blocked efficiently the DR1-restricted
recognition by M1-specific CTL lines. This result is consis-
tent with the existence of separate processing pathways for
the two classes of MHC molecules. However, interpretation
of the chloroquine effect on class II-mediated presentation
is complicated by the fact that the invariant chain, associated
intracellularlywith the class II a/(3 dimer until their delivery
into a post-Golgi acidic compartment (33), is dissociated from
the a/0 dimers at a slower rate in the presence of chloro-
quine (32).
The most direct evidence for the existence of separate
pathways for processing of endogenous antigens was obtained
with Brefeldin A. This drug causes a rapid redistribution of
the Golgi compartment to the endoplasmic reticulum, thus
preventing export of newly synthesized proteins from the en-
doplasmic reticulum (38-40). Whereas the A2-restricted rec-
ognition of VAC-M1-infected cells was totally abolished by
treatment with Brefeldin A, this drug caused only a modest
inhibition of the DR1-restricted recognition. Therefore, pep-
tide loading of endogenously processed antigen onto class
II molecules does not take place in the endoplasmic retic-
ulum, implying separate processing pathways for the two
classes ofMHC molecules. Under certain conditions, Brefeldin
A can inhibit presentation of exogenous antigen by class II
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molecules (41). This inhibition was similar to that observed
in cells treated with cycloheximide, indicating a need for newly
synthesized class II molecules in the presentation of exoge-
nous antigen. In the present study, a 5-h treatment with
Brefeldin A of the target cells infected with a recombinant
vaccinia virus was obviously insufficient to deplete the in-
ternal pool o£ class II molecules. A more pronounced inhibi-
tion by Brefeldin A of class II-restricted presentation was
observed by others (26) in cells infected for 5 h with influenza
virus. It is conceivable that the kinetics of class II molecule
transport from the endoplasmic reticulum to the cell surface
is affected differentially by these two viruses.
The evidence that class II-mediated presentation of en-
dogenously processed antigen is not dependent on loading
of peptides in the endoplasmic reticulum is consistent with
the finding of Sweetser et al. (14) that a pre-processed cyto-
plasmic peptide containing overlapping epitopes for class l-
and class II-restricted T cells was presented by the class I
but not by the class II molecules. One possible explanation
for the inability of class II molecules to utilize the class I
pathway ofpresentation is that the invariant chain associated
with newly synthesized class II molecules may prevent pep-
tide binding (25, 42). Peptide loading onto class II molecules
would occur only in a post-Golgi compartment, where the
invariant chain is proteolytically cleaved from the a/(3 dimers
(33). This model does not rule out the possibility that cer-
tain peptides with high affinity for the class II molecule may
be able to bind in the presence of the invariant chain. One
distinction between the endogenous pathways for the two
classes of MHC molecules may be that cytosolic peptides de-
rived from degraded proteins translocate into the endoplasmic
reticulum but not into the compartment for class II-medi-
ated presentation, whereas certain cytosolic proteins translo-
cate into the latter compartment.
The processing pathway for presentation of cytosolic pro-
teinsby class II molecules must involve some targeting mech-
anism that translocates these proteins into the compartment
where processing for class II-mediated presentation takesplace,
presumably a post-Golgi compartment . The current evidence
cannot distinguish whether cytosolic proteins destined to this
compartment must translocate first to the cell surface for re-
internalization or can be translocated directly into the proper
intracellular vesicle. In either case, a specific mechanism is
required that will target cytosolic proteins to the proper des-
tination, and the immunological implications of class 11-re-
stricted presentation ofendogenous antigen remain unchanged.
Translocation ofcytoplasmic proteins into lysosomes (43) and
autophagy (44) are both mechanisms that could be utilized
for class II-mediated presentation. Although lysosomes are
generally regarded as a terminal destination, it remains to
be established whether peptides generated by lysosomal degra-
dation can bind to functional class II molecules. Alternatively,
translocation of cytoplasmic proteins directly into endosomes
may also occur.References
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